Press release
Deadline coming up on August 9th in Lawsuit for Investors in AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

A Deadline is coming up on August 9, 2021 in the lawsuit for certain investors in AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX).
Investors who purchased shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) have certain options and there are strict and short deadlines running. Deadline: August 9, 2021. NASDAQ: ACRX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) common shares between March 17, 2020 and February 12, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 17, 2020 and February 12, 2021, the defendants made false and/or misleading statements and/or failed to disclose that: AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA, that as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays, that the foregoing conduct subjected the Company to increased regulatory scrutiny and enforcement, and that as a result, the Company's public statements were materially false and misleading at all relevant times. Those who purchased shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) have certain options and should contact the Shareholders Foundation.
Those who purchased shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
                     Copy
                  
                 Please set a link in the press area of your homepage to this press release on openPR.  openPR disclaims liability for any content contained in this release. 
    You can edit or delete your press release Deadline coming up on August 9th in Lawsuit for Investors in AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) here
News-ID: 2332137 • Views: …
More Releases from Shareholders Foundation
 
                                            
                                                    Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE:  …                                                
                                            
                                        
                                            An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…  
                                        
                                     
                                            
                                                    Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …                                                
                                            
                                        
                                            An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. 
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…  
                                        
                                     
                                            
                                                    Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …                                                
                                            
                                        
                                            An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…  
                                        
                                     
                                            
                                                    Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025                                                
                                            
                                        
                                            A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. 
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…  
                                        
                                    More Releases for AcelRx
                                                    Pain Management Therapeutics Market Future Business Opportunities 2025-2032 | Ac …                                                
                                            
                                        
                                            Latest Report, titled "Pain Management Therapeutics Market" Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The Pain Management Therapeutics market has been…  
                                        
                                    
                                                    Pain Management Therapeutics Market Future Business Opportunities 2024-2031 | Ac …                                                
                                            
                                        
                                            The Latest research report on the Pain Management Therapeutics Market 2024 provides a comprehensive analysis of the current market landscape, with forecasts extending to 2031. This study combines qualitative and quantitative insights to highlight significant market developments, challenges, competitive dynamics, and potential opportunities and trends shaping the Pain Management Therapeutics Market. The report covers market size, recent trends, growth projections, market share, and development status. Additionally, it examines government policies,…  
                                        
                                    
                                                    Pain Management Therapeutics Market See Incredible Growth 2024-2031 | AcelRx Pha …                                                
                                            
                                        
                                            Latest Report, titled "Pain Management Therapeutics Market" Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The Pain Management Therapeutics market has been…  
                                        
                                    
                                                    Investigation announced for Long-Term Investors in NASDAQ: ACRX shares) over pot …                                                
                                            
                                        
                                            Certain directors of AcelRx Pharmaceuticals, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Investors who are current long term investors in AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: ACRX stocks follows a lawsuit filed against AcelRx Pharmaceuticals, Inc.  over…  
                                        
                                    
                                                    Lawsuit filed for Investors in shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: A …                                                
                                            
                                        
                                            An investor, who purchased shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), filed a lawsuit over alleged violations of Federal Securities Laws by AcelRx Pharmaceuticals, Inc.
Investors who purchased shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) have certain options and for certain investors are short and strict deadlines running. Deadline: August 9, 2021. NASDAQ: ACRX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Redwood City, CA based…  
                                        
                                    
                                                    Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era |  …                                                
                                            
                                        
                                            The research report on Pain Management Market provides a comprehensive analysis of the market status and development trend, including types, applications, growth, opportunities, rising technology, competitive landscape and product offerings of key players. Pain Management Market report covers the present and past market scenarios, market development patterns, and is likely to proceed with a continuing development over the forecast period.
Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut…